Meeting Impression | PCSK9 inhibition: Science, outcomes & guidanceAugust 25, 2018 - Munich, Germany
See below to download the Meeting Impression
This EBAC-accredited symposium was held during ESC 2018 in Munich, Germany. Prof. Ference, prof. Robinson and prof. Kastelein discussed PCSK9 as validated therapeutic target in CVD and translation into clinical practice. Combined data on PCSK9 inhibitors and statins were presented by prof. Ference, showing biologically and therapeutically equivalent effects of these two drugs on CV risk reduction. The selection of eligible patients for PCSK9 inhibition therapy was presented by prof. Robinson, focusing on patients at risk and phenotypes. Prof. John Kastelein discussed issues surrounding prescription of PCSK9 inhibitors and future perspective, with focus on other lipid-lowering therapies in statin-intolerant patients.
This is a summary of the PACE symposium entitled 'PCSK9 inhibition: Science, outcomes & guidance', held during ESC in Munich, Germany, on August 27, 2018.
The educational objectives of the symposium were to:
- Recognize PCSK9 as validated therapeutic target in CVD
- Acknowledge that PCSK9 inhibitors and statins have equivalent effects on Cv risk reduction
- Understand how eligible patients can be selected for PCSK9 inhibition therapy
- Discuss issues surrounding prescription of PCSK9 inhibitors
- Recognize other lipid-lowering therapies in statin-intolerant patients
Prof. Brian Ference, MD (Cambridge, United Kingdom): PCSK9 as target for treatment: The genetic validation
Prof. Jennifer Robinson, MD (Iowa, USA): Novel PCSK9 outcomes in perspective: Lessons from FOURIER & ODYSSEY
Prof. John JP Kastelein, MD (Amsterdam, The Netherlands): Targeting PCSK9 in clinical practice: Guidance & future